Thus, these cardenolides could be developed as p53/MDM2 interaction- and tumor microenvironment-targeted cancer chemotherapeutic agents, and (+)-strebloside seems to be more promising than digoxin for this purpose. This evidence concerns the gene TP53 and cancer.